Insights By Accel
 Series
Episode 
20

Healthcare Landscape in India

December 7, 2018
31 Mins
 Read

Healthcare Landscape in India

Insights By Accel
 #
20
Healthcare Landscape in India
 Mins Read
31 Mins
You can also listen on

Summary

We continue with the #INSIGHTSPodcast Series and in this episode, we focus on the healthcare sector and discuss opportunities and the market landscape using examples from the Accel portfolio. To talk about this exciting topic, We have Barath & Radhika, Principal & Sr Associate at Accel whose core focus investment areas are in Life sciences, Medtech and digital health.

Image for post

On this podcast, we discuss the healthcare landscape in India using examples from the Accel portfolio and what to look for while building out a healthcare company from India :

Examples from Accel portfolio on problems being solved in healthcare for global markets

  • Lifesciences
    What is life sciences — the model of an IP led lifesciences company solving global problems
  • Mitra Biotech
    Why did they choose to start in India?
    The solution to an age old problem — How do you understand the effects of drugs on tumors without bombarding a patient with the drugs
  • Zumutor
    Building a platform to develop molecules for improving drug delivery to cancer cells
  • Healthcare Delivery
    The problems with the healthcare delivery in India
    Moving care back to the home — counter intuitive insight and how Portea plugs the gaps in the delivery space
  • Digital health
    Onco.com — using digital distribution to disrupt the current value chain and deliver better care for patients
  • Using AI to deliver healthcare in the diagnostics space — How sigtuple uses digital distribution and AI to deliver healthcare and diagnose correctly.

The Indian Advantage — Why healthcare is attractive in India

  • Capital efficiency from being in India
    3x-5x advantage in capital required from building from India
    Talent, Infrastructure arbitrage from India — The Indian pharma story for next wave of lifesciences
  • Speeding things up — How India helps speed up development
    The regulatory advantage — lesser regulations for initial development of drugs. Using the initial momentum and taking the drugs to more regulated markets for trials — the difficulty of trials in the Indian market
  • Examples where the thesis on cost and time plays out
    The estimates from Axio — getting to market with 1/10th the capital and 60% of the time to get to market with a great product
    Setting the standards in India so the product goes global — no compromise on quality
Subscribe to get the latest from Accel emailed directly to you
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

The healthcare business — things to consider while getting into the healthcare sector

  • The trust process — building trust, and the time and effort it takes to build trust
  • Importance of IP — having a good IP and using peer-reviewed publications for validation and marketing
  • Patent portfolio and defensiblity of patents — defending incremental IP and not infringing existing patents, and filing patents to get it out in the world
  • The team — building a team as the company grows, and the expertise required; the differences between life sciences, and non-life science businesses
  • The Indian story — shift from communicable to chronic disease, infrastructure gap, mobile first country and the advantage technology provides in such an environment.
Subscribe to get the latest from Accel emailed directly to you
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No result to show
We couldn't find what you're looking for